Next-IO™ A2AR Therapeutic Monoclonal Antibody Program

About This Program

This program aims to develop A2AR therapeutic monoclonal antibody for non-small cell lung cancer immunotherapy.

Rationale for our program:

These data support the rationale for the development of the first-in-class human A2AR Abs for NSCLC.

A2AR

The adenosine A2A receptor (A2AR) belongs to the G protein-coupled receptor (GPCR) family A or rhodopsin receptor family. Adenosine receptors include four subtypes (A1R, A2AR, A2BR, and A3R) that are activated by extracellular adenosine. A2AR and A1R are widely distributed throughout the central nervous system and surrounding, while low-density A2BR and A3R are present in the brain.

Research to date strongly supports the A2a receptor as a new way of immunotherapy:

Next-IO™ A2AR Therapeutic Monoclonal Antibody ProgramFig.1 A2aR blockade in the tumor microenvironment. (Leone, 2015)

Supporting Data

Next-IO™ A2AR Therapeutic Monoclonal Antibody Program(Willingham, 2018)

NSCLC

Next-IO™ A2AR Therapeutic Monoclonal Antibody Program

Ongoing Clinical Trials

Program Mangement

We have extensive knowledge of end-to-end program development. For each program, we are committed to delivering the final complete program to our clients within 1.5 years before entering the IND stage.

Next-IO™ A2AR Therapeutic Monoclonal Antibody Program

Cooperation

Creative Biolabs is looking for potential partners (include but not limit to major pharma or biotech firms) to develop A2AR therapeutic monoclonal antibody program together. Our scientists are dedicated to bringing years of valuable experience to our partner and achieve a meaningful partnership together. For any partners interested in our Next-IO™ programs, Creative Biolabs welcomes collaboration.

Here are two ways for your choice, and please contact us for more details.

1) Collaborate with us and co-develop the programs from the discovery phase to IND enabling. Costs will be shared.

2) Become a licensed candidate for our programs.

With our quality control protocol and knowledge of global regulatory requirements, we can help our partners further their programs with more chances to succeed. Look forward to cooperating with you in the near future.

References

  1. Leone, R.D.; et al. A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy. Computational and structural biotechnology journal. 2015, 13: 265-272.
  2. Inoue, Y.; et al. Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer. Oncotarget. 2017, 8(5): 8738.
  3. Willingham, S.B.; et al. A2AR Antagonism with CPI-444 induces antitumor responses and augments efficacy to anti–PD-(L) 1 and anti–CTLA-4 in preclinical models. Cancer immunology research. 2018, 6(10): 1136-1149.

For Research Use Only | Not For Clinical Use

Online Inquiry
Copyright © 2024 Creative Biolabs. All Rights Reserved.
ISO 9001 Certified - Creative Biolabs Quality Management System.